| Literature DB >> 33492078 |
Ernst Janse van Rensburg1, Christina L Ryu1,2,3, Emmanouil Rampakakis4, Natalia Vila1,5, Errol W Chan1,6, John C Chen1.
Abstract
PURPOSE: To investigate the role of Type 2 macular neovascularization with subsequent subretinal fibrosis in the pathogenesis of outer retinal tubulation (ORT).Entities:
Mesh:
Substances:
Year: 2021 PMID: 33492078 PMCID: PMC8384246 DOI: 10.1097/IAE.0000000000003127
Source DB: PubMed Journal: Retina ISSN: 0275-004X Impact factor: 4.256
Incidence of Different Types of MNV in the Non-ORT and ORT Cohorts
| Non-ORT | ORT |
| |
| Type of initial MNV on OCT, n (%) | |||
| Type 1 | 56 (62.9) | 4 (7.3) | <0.001 |
| Type 2 | 6 (6.7) | 13 (23.6) | |
| Mixed Type 1 and Type 2 | 27 (30.3) | 38 (69.1) | |
| Type of initial MNV on OCT, n (%) | |||
| Type 1 | 56 (62.9) | 4 (7.3) | <0.001 |
| All Type 2 | 33 (37.1) | 51 (92.7) | |
| Type of initial MNV on FA, n (%) | |||
| Occult | 60 (71.4) | 17 (33.3) | <0.001 |
| Mixed + classic | 24 (28.6) | 34 (66.7) | |
| Mixed | 13 (15.5) | 13 (25.5) | |
| Classic | 11 (13.1) | 21 (41.2) | |
| Size of MNV on FA, n (%) | |||
| <1 DA | 32 (37.2) | 7 (13.7) | <0.001 |
| 1–1.5 DA | 36 (41.9) | 20 (39.2) | |
| >1.5DA | 18 (20.9) | 24 (47.1) | |
| Diagnosis, n (%) | |||
| AMD | 49 (55.1) | 46 (83.6) | 0.002 |
| RAP | 31 (34.8) | 7 (12.7) | |
| PCV | 9 (10.1) | 2 (3.6) | |
| Initial membrane by diagnosis, n (%) | |||
| AMD | |||
| Type 1 | 31 (63.3) | 3 (6.5) | <0.001 |
| Type 2 | 3 (6.1) | 11 (23.9) | |
| Mixed Type 1 and Type 2 | 15 (30.6) | 32 (69.6) | |
| RAP | |||
| Type 1 | 18 (58.1) | 1 (14.3) | 0.095 |
| Type 2 | 3 (9.7) | 2 (28.6) | |
| Mixed Type 1 and Type 2 | 10 (32.3) | 4 (57.1) | |
| PCV | |||
| Type 1 | 7 (77.8) | 0 (0.0) | 0.109 |
| Mixed Type 1 and Type 2 | 2 (22.2) | 2 (100.0) |
P- value is <0.001 for both comparison of two levels and three levels.
Final Multivariate Model for ORT Development On Selection of Significant Variables
| Odds Ratio | 95% CI |
| ||
| Lower | Upper | |||
| Mixed + classic versus occult | 4.0 | 1.0 | 15.2 | 0.044 |
| All Type 2 (predominant and minimal) versus no Type 2 | 22.2 | 6.1 | 80.8 | <0.001 |
| Initial size of MNV >1.5 DA versus = <1 DA | 9.0 | 1.8 | 44.0 | 0.007 |
| Initial size of MNV 1–1.5 DA versus = <1 DA | 5.1 | 1.1 | 24.2 | 0.041 |
| Subretinal fibrovascular tissue yes versus No | 3.1 | 1.1 | 8.5 | 0.030 |
Fig. 1.Parts A–C. Initial SD-OCT images depicting fibrous stands in a rounded subretinal space. The SD-OCT images of three patients (A–C) with Type 2 MNV are shown. Fibrous strands (arrowheads) can be seen connecting the underside of the outer retina with the underlying fibrovascular membrane. Note the rounded edges (arrows) of the subretinal space. All three patients developed ORT.
Fig. 2.Part A–D sequential SD-OCT images depicting progression from Type 2 MNV to ORT formation. A. A Type 2 MNV with intraretinal and subretinal fluid. The subretinal space has a rounded edge with fine lines (outlined arrowhead) spreading from the fibrous scar to the underside of the retina. The free edge of the ELM is tacked down on the fibrous tissue (solid white arrowhead). B–D. After anti-VEGF treatment, the subretinal space collapse with compacting of the fibrous scar and the free edge of the ELM is seen to progressively scroll until closed ORTs are formed.
Fig. 3.Parts A–E diagram of the proposed role of subretinal fibrosis in ORT formation. A. SD-OCT image of Type 2 MNV with strands (fibrin) spanning the subretinal space and attaching to the underside of the outer retina (same patient as in panel A of Fig. 1). B–E. (B). Presentation; (C) one month later after first anti-VEGF injection; (D) two months later after two injections; (E) three months later after third anti-VEGF injection ensuing contraction of the subretinal fibrosis results in compacting of the subretinal scar and ultimate ORT formation. Black arrows indicate the directions of presumed fibrous contraction.
Fig. 4.Parts A and B the spatial relationship between MNV and ORT in macular atrophy. A. This patient presented with a Type 3 MNV (RAP lesion). B. With anti-VEGF therapy, signs of a neovascular process disappeared and there is development of macular atrophy. The epicenter of the initial Type 3 MNV is indicated (upward arrows) along with the location of the single ORT that developed (downward arrows). This case illustrates ORT forming near the location of a preceding MNV in the context of macular atrophy.